GlucoTrack, Inc. develops medical technology for people with diabetes, centered on a long-term, fully implantable continuous blood glucose monitoring system. Company news commonly covers the CBGM platform, FDA Investigational Device Exemption activity, preclinical and clinical-study disclosures, and peer-reviewed publications on sensor stability, accuracy, and implantable device performance.
Updates also include intellectual-property developments for proprietary sensor chemistry, intravascular lead design, and low-power electronics, along with financial results, research and development spending, capital actions, and conference presentations tied to the company’s diabetes device strategy.
Glucotrack (GCTK) will implement a 1-for-2 reverse stock split effective at the opening of trading on October 26, 2026.
Outstanding common shares will fall from 2,368,237 to approximately 1,184,119. Ownership percentages will remain unchanged except for fractional-share adjustments, which will round holdings up to whole shares. Glucotrack gives regaining compliance with Nasdaq’s $1.00 minimum bid price requirement as a reason for the split. Under a Nasdaq Hearings Panel exception, it must maintain a closing bid price of at least $1.00 each trading day until November 9, 2026. Failure to satisfy the exception could result in delisting. The company previously implemented a 1-for-15 reverse split on August 28, 2026.
Glucotrack (GCTK) subsidiary Lōkahi Therapeutics has publicly launched Qare, a platform for comparing users’ self-reported medication experiences, initially focused on GLP-1 medications.
The app is free on the App Store and Google Play. It groups users by medication and demographic profile to compare reported results, side effects and out-of-pocket costs, with comparisons presented in aggregate. Lōkahi expects to add other therapeutic categories through organic expansion and industry partnerships. The company believes the platform’s de-identified dataset may support future research and industry partnerships as its user base grows.
Glucotrack (GCTK) subsidiary Lōkahi Therapeutics announced its first international university asset-evaluation project with the University of Georgia and Universität Paderborn. The Fall 2026 initiative involves Georgia's Student Industry Fellows Program and Paderborn's garage33 entrepreneurship and innovation center. U.S. and German student teams will evaluate pharmaceutical and biotechnology assets developed, commercialized, or underprioritized outside the United States for potential U.S. licensing, acquisition, or further evaluation.
The project expands university-based capacity for internal asset identification and external engagements, building on the fee-for-service model established through Lōkahi's Innovate GBM engagement. Lōkahi sees additional revenue potential through sponsored projects, strategic collaborations, and asset-origination activities.
Glucotrack (GCTK) subsidiary Lōkahi Therapeutics introduced Qare, a comparative health platform expected to become publicly available on October 14, 2026.
Initially focused on GLP-1 medications, Qare is designed to let users document and analyze their treatment experiences alongside those of similar patients using different medications within the same therapeutic class. Developed through the ai² Accelerator, the platform compares patient experiences rather than only tracking individual records. Lōkahi expects additional therapeutic categories in future releases.
Glucotrack (GCTK) subsidiary Lōkahi Therapeutics will partner with Pepperdine E2B through ai2 Pipeline during the upcoming academic year. The collaboration will begin with full-time MBA students in a Pepperdine Graziadio Business School marketing course. Students will work alongside Lōkahi professionals to evaluate actual therapeutic opportunities and develop recommendations.
In its first year, Lōkahi’s separate ai2 Futures Lab engaged 64 students and identified more than 45 potential assets. Several have advanced into active pipeline discussions. Lōkahi intends the Pepperdine project to expand its capacity to find and assess therapeutic assets.
Glucotrack (GCTK) priced a best-efforts public offering expected to generate approximately $3.1 million in gross proceeds.
The offering includes 169,388 common shares at $2.04 per share and pre-funded warrants to purchase up to 1,350,220 shares at $2.039 per warrant. The warrants are offered to certain investors instead of common shares. Gross proceeds are before placement agent fees and offering expenses. The offering was priced at-the-market under Nasdaq rules and is expected to close on or about September 25, 2026, subject to customary closing conditions. Dawson James Securities is the sole placement agent.
Glucotrack (GCTK) subsidiary Lōkahi Therapeutics secured a fee-for-service engagement with Innovate GBM for two ai² PIPELINE project teams. Innovate GBM is the first outside organization to use Lōkahi’s asset-identification process. The teams will identify and evaluate therapeutic assets available for licensing and development in glioblastoma and other brain tumors.
The engagement extends a process previously used for Lōkahi’s own asset discovery to an external sponsor. Innovate GBM will independently decide whether to pursue any asset the teams identify.
Glucotrack (GCTK), operating Lōkahi Therapeutics, issued a strategic update on LT-100, its ai² platform expansion, and clinical development priorities.
The company completed its strategic business combination on July 14, with Glucotrack Technologies continuing as a wholly owned subsidiary focused on continuous blood glucose monitoring, while Lōkahi concentrates on therapeutic asset development and ai² platform growth. Lōkahi’s near-term priority is LT-100, a biologic for osteoarthritis knee pain. A clinical protocol has been submitted for regulatory review, and Lōkahi is targeting study initiation in the near term, subject to regulatory feedback, to test once-weekly subcutaneous injections versus a historical 15-week intradermal regimen.
The ai² platform comprises ai² Pipeline, ai² Talent, and ai² Accelerator. The ai² Pipeline, supported by over 14 university partners, applies due diligence across more than 12,000 late-stage programs and has identified over 45 assets meeting initial criteria, with some in preliminary business development discussions. Lōkahi reiterates its model: discover, advance, and monetize near-term, value-creating therapeutics, often before completion of registration trials.
Lōkahi Therapeutics (GCTK), a subsidiary of Glucotrack, announced that The University of Alabama’s Culverhouse College of Business will continue participating in its ai² Pipeline division for the upcoming academic year.
The renewed collaboration extends a hands-on program in which University of Alabama students evaluate real-world biopharmaceutical business development and asset assessment opportunities. In its first year, the ai² Futures Lab engaged 64 students and identified more than 45 potential therapeutic assets, with several moving into active pipeline discussions. Students will work alongside industry professionals on activities such as market analysis, intellectual property assessment, regulatory strategy, and commercialization planning. Their work will culminate in recommendations that may inform partnership discussions, licensing opportunities, or potential acquisitions, while expanding Lōkahi’s sourcing reach and analytical capacity in a capital-efficient manner.
Glucotrack (GCTK) entered into definitive agreements for approximately $11.5 million in aggregate principal amount of convertible notes. The financing includes about $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the total principal amount reflecting a 22% original issue discount. The notes are initially convertible at $3.12 per share, and participating investors will also receive warrants exercisable at $7.50 per share. Dawson James Securities acted as sole placement agent. Glucotrack operates the Lōkahi platform and develops investigational long-term implantable continuous blood glucose monitoring technology.